A drug currently approved for osteoporosis treatment has been shown to reduce bone loss in a study of mice with oral cancer, suggesting it could serve as an important supplemental therapy in patients with head and neck cancers that erode bone. In this study, the drug treatment also was associated with smaller tumors — an unexpected result.